Spectrum Pharma rises on smaller-than-expected loss

Spectrum Pharmaceuticals

11/11/2021 12:49

** Pharmaceutical company's shares  SPPI.O  up ~5% at $2.14
premarket 
    ** Co on Wednesday posted a smaller-than-expected Q3 loss
 urn:newsml:reuters.com:*:nBw1GNZkGa 
    ** Co said manufacturing deficiencies hindering the approval
of its drug Rolontis are expected to be addressed by the end of
the year
    ** In August, U.S. FDA declined to approve Rolontis, citing
deficiencies related to manufacturing 
    ** Rolontis is meant for treatment of neutropenia, or low
white blood cells, in patients receiving cancer drugs
    ** Up to Wednesday's close, stock had fallen 40.2% this year

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com))